Navigation Links
BioLife Solutions Granted Japanese Biopreservation Patent
Date:11/18/2009

BOTHELL, Wash., Nov. 18 /PRNewswire-FirstCall/ -- BioLife Solutions, Inc. (OTC Bulletin Board: BLFS), a leading developer, manufacturer, and marketer of proprietary cGMP hypothermic storage and cryopreservation media products for cells, tissues, and organs, today announced that it has been granted a Japanese patent for an application that includes claims related to protecting cells from injury and death caused by cold temperatures used in biopreservation. The patent is titled "Inclusion of Apoptotic Regulators in Solutions for Cell Storage at Low Temperature," and BioLife was previously granted US and European patent protection for this intellectual property.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090814/BIOLIFELOGO)

Mike Rice, BioLife's chairman and CEO, noted the new patent is a direct result of BioLife's ongoing efforts to increase the value of its intellectual property portfolio and enable additional product and licensing revenue streams for BioLife. "In addition to this granted Japanese patent, two international Patent Cooperation Treaty (PCT) applications were recently published covering claim sets related to the collection, storage, transport, and banking of whole blood and also birth tissue including cord blood. I'm pleased that our research and development activities continue to produce discoveries and potential innovations in the biopreservation field."

About BioLife Solutions, Inc.:

BioLife Solutions develops and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor(TM) platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's cGMP products are serum-free and protein-free, fully defined, and formulated to reduce preservation-induced, delayed-onset cell damage and death. BioLife's enabling technology provides research and clinical organizations significant improvement in post-preservation cell and tissue viability and function. For more information please visit www.biolifesolutions.com.

http://www.marrow.org/This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    Media Relations:                        Investor Relations:
    Len Hall                                Matt Clawson
    Allen & Caron Inc                       Allen & Caron Inc
    (949) 474-4300                          (949) 474-4300
    len@allencaron.com                      matt@allencaron.com

SOURCE BioLife Solutions, Inc.


'/>"/>
SOURCE BioLife Solutions, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich
2. BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
3. BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement
4. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
5. Rutgers University Cell and DNA Repository Adopts BioLife Solutions CryoStor(TM) as Standard Biopreservation Media
6. Improved Cryopreservation Outcomes in Potential $100B Tissue Engineering Market Enabled by BioLife Solutions CryoStor(TM)
7. BioLife Solutions Launches BioPreservation Today(R) Industry Newsletter
8. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
9. BioLife Solutions Completes Safety Studies on HypoThermosol(R) and CryoStor(TM)
10. BioLife Solutions Granted European Biopreservation Patent
11. BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Switzerland , February 27, 2017 A ... has indicated that researchers using animals in their research treat them ... from 26 countries, and detailed analysis of the results indicates that ... Europe to put into practice the principles of the ... ...
(Date:2/27/2017)... PRINCETON, N.J. and HAMILTON, ... Advaxis, Inc. (NASDAQ: ADXS ) ... late-stage biopharmaceutical companies focused on developing cancer immunotherapies, ... license to develop a novel cancer immunotherapy agent ... technology with SELLAS, patented WT1 targeted heteroclitic peptide ...
(Date:2/26/2017)... ... , ... Rob Lowe is a well recognized television personality, so it seems ... issues that are important to the American public and important to society at large. ... hot topic around the world for a few years. , The climate and how ...
(Date:2/24/2017)... , ... February 24, 2017 , ... Chef Jodi Abel ... scene. Making stops in several cities, she gained a number of delicious recipes ... in Stellenbosch, a town in South Africa’s Western Cape province. It is internationally ...
Breaking Biology Technology:
(Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... The global synthetic-biology market ... billion by 2021, growing at a compound annual growth rate ... overview of the global markets for synthetic biology. - Analyses ... 2016, and projections of compound annual growth rates (CAGRs) through ...
Breaking Biology News(10 mins):